Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

by · The Markets Daily

Aclarion, Inc. (NASDAQ:ACON – Get Free Report) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 24,767 shares, a drop of 60.0% from the August 15th total of 61,992 shares. Based on an average daily trading volume, of 83,475 shares, the short-interest ratio is presently 0.3 days. Currently, 0.9% of the company’s stock are sold short.

Insider Activity

In other news, Director Ryan Bond acquired 21,122 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were purchased at an average price of $2.37 per share, with a total value of $50,059.14. Following the transaction, the director directly owned 76,122 shares in the company, valued at approximately $180,409.14. This represents a 38.40% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have purchased 51,863 shares of company stock valued at $125,670. 0.01% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ACON shares. Weiss Ratings upgraded shares of Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Wall Street Zen raised Aclarion from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Ascendiant Capital Markets increased their price objective on Aclarion from $7.00 to $7.50 and gave the company a “buy” rating in a report on Friday, May 29th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Aclarion currently has a consensus rating of “Hold” and an average target price of $7.50.

View Our Latest Stock Report on Aclarion

Aclarion Stock Performance

Shares of NASDAQ ACON opened at $2.60 on Friday. The company has a market cap of $7.49 million, a PE ratio of -0.35 and a beta of 1.24. The business has a 50-day simple moving average of $2.50 and a two-hundred day simple moving average of $2.95. Aclarion has a fifty-two week low of $1.95 and a fifty-two week high of $12.03.

Aclarion (NASDAQ:ACON – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.07). Aclarion had a negative net margin of 10,948.81% and a negative return on equity of 59.34%. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. On average, sell-side analysts predict that Aclarion will post -4.51 earnings per share for the current fiscal year.

About Aclarion

(Get Free Report)

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.

Featured Articles